Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 4/20 | 0.59 |
| ▸ | CRBN | Q96SW2 | 4/20 | 0.59 |
| ▸ | BCHE | P06276 | 8/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
| ▸ | SNRNP200 | O75643 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25079576 | 0.92 | DDB1 (0.56) | DDB1CRBNBCHEKDM4E | |
| SCHEMBL25079206 | 0.83 | ESR1 (0.51) | DDB1CRBNSLC6A2 | |
| SCHEMBL25079638 | 0.79 | DDB1 (0.72) | DDB1CRBNALOX5SNRNP200 | |
| SCHEMBL25079659 | 0.79 | CRBN (0.58) | DDB1CRBNBCHEKDM4EMAPK1 | |
| SCHEMBL23120531 | 0.79 | DDB1 (0.52) | DDB1CRBNKDM4ECACNA2D1 | |
| SCHEMBL23121402 | 0.78 | DDB1 (0.49) | DDB1CRBN | |
| SCHEMBL25079326 | 0.77 | DDB1 (0.49) | DDB1CRBNBCHEKDM4EMAPK1 | |
| SCHEMBL25079581 | 0.76 | CRBN (0.57) | DDB1CRBNBCHEKDM4E | |
| SCHEMBL23120468 | 0.75 | CRBN (0.58) | DDB1CRBN | |
| SCHEMBL22534784 | 0.71 | DDB1 (0.56) | DDB1CRBNKDM4EALOX5SNRNP200 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023023531-A1 | ESTROGEN RECEPTOR DEGRADERS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. (US) | 2023-02-23 | — | — | WO | disclosed |